<DOC>
	<DOCNO>NCT00735761</DOCNO>
	<brief_summary>The purpose study evaluate episode duration herpes labialis recurrence immunocompromised patient treat ME-609 Acyclovir .</brief_summary>
	<brief_title>Study ME-609 Acyclovir Treatment Herpes Simplex Labialis Immunocompromised Patients</brief_title>
	<detailed_description>The objective study evaluate episode duration herpes labialis recurrence , follow 5-day treatment 5-time daily topical administration ME-609 acyclovir cream , immunocompromised adult , 18 year old . This interim report summarize result short-term observation , i.e. , initial study recurrence . A final study report prepare long-term follow-up complete .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>History recurrent herpes labialis least two recurrence twelve month prior study . Stable HIV infection CD4+ Tcell count 100 500/mm3 Systemic treatment antiviral agent corticosteroid within two week prior treatment period , except antiretroviral treatment HIV subject Topical treatment antiviral agent corticosteroid within around oral area within two week prior study drug administration Significant skin condition occur area typically affect herpes recurrence Nursing pregnancy Concurrent cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>